Xenetic Biosciences, Inc. cotiza a 2.12 USD y tiene una capitalización bursátil de $5M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherap…
| Periodo | 2026-03 | 2025-11 | 2025-08 | 2025-05 |
|---|---|---|---|---|
| Real | $-0.22 | $-0.33 | $-0.45 | $-0.59 |
| Estimado | $-0.52 | $-0.49 | $-0.64 | $-0.72 |
| Sorpresa | +57.7% | +32.7% | +29.7% | +18.1% |
| Métrica | XBIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -95.2% | -38.6% | -56.6% |
| Net Margin | -90.1% | -33.6% | -56.5% |
| FCF Margin | — | -13.9% | — |
| ROE | -36.3% | -40.4% | +4.1% |
| ROA | -32.0% | -32.0% | -0.0% |
| Current Ratio | 8.32 | 2.84 | +5.48 |
| Debt / Equity | — | 0.28 | — |